Morgan Stanley Call 460 AMGN 20.0.../ DE000ME6QP90 /
| 2024-05-23 8:39:36 PM | Chg.-0.020 | Bid10:00:33 PM | Ask10:00:33 PM | Underlying | Strike price | Expiration date | Option type |
|---|---|---|---|---|---|---|---|
| 0.470EUR | -4.08% | - Bid Size: - |
- Ask Size: - |
Amgen Inc | 460.00 USD | 2025-06-20 | Call |
GlobeNewswire
05-23
Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine recept...
GlobeNewswire
05-22
Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilar...
GlobeNewswire
05-21
Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update
GlobeNewswire
05-21
Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a bios...
GlobeNewswire
05-15
Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member
GlobeNewswire
05-14
Accumulus Synergy Sponsors Revolutionary Healthcare Data Standard, Advancing Towards Global Dossier
GlobeNewswire
05-14
Nouscom Appoints Leading Cancer Drug Development Expert, Neil Gallagher, MD, PhD, as Independent Adv...
GlobeNewswire
05-13
TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
05-09
argenx Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
05-08
CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 ...
GlobeNewswire
05-08
CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
05-08
Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination ...
